DOSIsoft Unveils DOSIsoft Theranostics to Revolutionize Nuclear Medicine Software Innovation
On May 26, 2026, with a powerful announcement ahead of SNMMI 2026, DOSIsoft introduced DOSIsoft Theranostics, a specialized entity committed to enhancing software innovation in the realm of personalized nuclear medicine and theranostics. DOSIsoft, renowned for its cutting-edge dosimetry software serving radiation oncology and nuclear medicine, is now poised to broaden its impact through focused development in the theranostics sector.
This new organization is built on DOSIsoft's more than 20-year journey in the medical software landscape, leveraging their extensive experience to address the specific needs of theranostics — a discipline at the intersection of therapies and diagnostics. Theranostics is evolving, enabling the integration of targeted therapies with diagnostic capabilities, paving the way for personalized treatments tailored to individual patient needs. DOSIsoft Theranostics aims to facilitate broader use within clinical practice, enhancing the synergy between diagnostics and therapeutic approaches.
A significant highlight of this initiative is PLANET®, DOSIsoft’s flagship software platform. PLANET® has transitioned from its origins in external beam radiation therapy treatment planning into a sophisticated solution reflecting the multifaceted landscape of modern nuclear medicine. This platform features advanced voxel-based multi-radionuclide dosimetry, along with comprehensive DICOM interoperability, making it integral for clinical workflows across various imaging modalities. The FDA has cleared this product as 510(k), and it also holds CE marking, indicating its compliance with rigorous safety and efficacy standards in healthcare settings.
DOSIsoft Theranostics is strategically designed to meet the unique demands of sophisticated healthcare environments. As the field of nuclear medicine continues to evolve, this new entity provides a dedicated focus to accelerate the development of innovative software solutions that are crucial for enhancing patient outcomes. Industry experts recognize that treatment personalization not only improves patient care but also streamlines clinical operations through enhanced data-driven workflows.
Marc Uszynski, CEO of DOSIsoft, articulated the vision behind this endeavor. He emphasized that creating a specialized theranostics organization symbolizes DOSIsoft's long-standing dedication to this rapidly growing field, granting it the flexibility and focus needed to foster innovation, nurture new partnerships, and extend the applications of theranostics on a global scale. In doing so, DOSIsoft Theranostics is set to become a trusted software partner within the healthcare ecosystem, allowing clinical practitioners to leverage cutting-edge technology in their methodologies.
Furthermore, with comprehensive software tools and an emphasis on continual research and clinical trials, DOSIsoft Theranostics will play a pivotal role in advancing both global health initiatives and individualized therapy monitoring. DOSIsoft's extensive network comprising over 800 hospital centers in 80 countries will be instrumental in rolling out these innovative solutions across various settings.
The organization’s presence at SNMMI 2026 (#1358) will showcase its commitment and expertise in promoting personalized care in nuclear medicine. By fusing advanced diagnostics with patient-specific therapies, DOSIsoft Theranostics promises to significantly enhance treatment efficacy and overall patient safety. As the industry gears up for the future of healthcare, DOSIsoft Theranostics stands ready to lead the charge in redefining the landscape of nuclear medicine through software innovation and patient-centric solutions.
This new organization is built on DOSIsoft's more than 20-year journey in the medical software landscape, leveraging their extensive experience to address the specific needs of theranostics — a discipline at the intersection of therapies and diagnostics. Theranostics is evolving, enabling the integration of targeted therapies with diagnostic capabilities, paving the way for personalized treatments tailored to individual patient needs. DOSIsoft Theranostics aims to facilitate broader use within clinical practice, enhancing the synergy between diagnostics and therapeutic approaches.
A significant highlight of this initiative is PLANET®, DOSIsoft’s flagship software platform. PLANET® has transitioned from its origins in external beam radiation therapy treatment planning into a sophisticated solution reflecting the multifaceted landscape of modern nuclear medicine. This platform features advanced voxel-based multi-radionuclide dosimetry, along with comprehensive DICOM interoperability, making it integral for clinical workflows across various imaging modalities. The FDA has cleared this product as 510(k), and it also holds CE marking, indicating its compliance with rigorous safety and efficacy standards in healthcare settings.
DOSIsoft Theranostics is strategically designed to meet the unique demands of sophisticated healthcare environments. As the field of nuclear medicine continues to evolve, this new entity provides a dedicated focus to accelerate the development of innovative software solutions that are crucial for enhancing patient outcomes. Industry experts recognize that treatment personalization not only improves patient care but also streamlines clinical operations through enhanced data-driven workflows.
Marc Uszynski, CEO of DOSIsoft, articulated the vision behind this endeavor. He emphasized that creating a specialized theranostics organization symbolizes DOSIsoft's long-standing dedication to this rapidly growing field, granting it the flexibility and focus needed to foster innovation, nurture new partnerships, and extend the applications of theranostics on a global scale. In doing so, DOSIsoft Theranostics is set to become a trusted software partner within the healthcare ecosystem, allowing clinical practitioners to leverage cutting-edge technology in their methodologies.
Furthermore, with comprehensive software tools and an emphasis on continual research and clinical trials, DOSIsoft Theranostics will play a pivotal role in advancing both global health initiatives and individualized therapy monitoring. DOSIsoft's extensive network comprising over 800 hospital centers in 80 countries will be instrumental in rolling out these innovative solutions across various settings.
The organization’s presence at SNMMI 2026 (#1358) will showcase its commitment and expertise in promoting personalized care in nuclear medicine. By fusing advanced diagnostics with patient-specific therapies, DOSIsoft Theranostics promises to significantly enhance treatment efficacy and overall patient safety. As the industry gears up for the future of healthcare, DOSIsoft Theranostics stands ready to lead the charge in redefining the landscape of nuclear medicine through software innovation and patient-centric solutions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.